Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616001397404
Ethics application status
Approved
Date submitted
21/09/2016
Date registered
10/10/2016
Date last updated
4/02/2019
Date data sharing statement initially provided
4/02/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Intranasal Deposition of fluorescein-dyed Saline delivered by a Nasal Mesh Nebulizer (NMN) at different pulse frequencies in patients that have undergone Functional Endoscopic Sinus Surgery (FESS)
Scientific title
Intranasal Deposition of fluorescein-dyed Saline delivered by a Nasal Mesh Nebulizer (NMN) at different pulse frequencies in patients that have undergone Functional Endoscopic Sinus Surgery (FESS)

Secondary ID [1] 290190 0
AFT-MD-02
Universal Trial Number (UTN)
U1111-1187-8516
Trial acronym
Nasal Mesh Nebulizer Trial AFT-MD-02
Linked study record
Not applicable

Health condition
Health condition(s) or problem(s) studied:
Patients who undergone functional endoscopic sinus surgery 300335 0
Condition category
Condition code
Respiratory 300199 300199 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The participant will be randomly allocated to a treatment sequence which will determine the order in which the aerosol deposition assessments are performed. During each treatment period, the pulse frequency of the saline delivered by the device is different..
During each study period when the assessment is being conducted, it involves the following steps:
1. The nasal aerosol assessment involves the delivery into the nose 1-2mL of fluorescein-dyed saline. The device will deliver the dyed saline to each side of the nose. The study subject will apply the device at the site under the investigator's supervision
2. Endoscopic assessment will be performed immediately following the delivery of the dyed-saline with the NMN, and 5,10 and 15 minutes thereafter.
3. Once the endoscopic assessment at 15 minutes has been completed, a saline rinse will be provided to remove the any residual fluorescein-dyed saline with the nasal cavity.
Steps 1-3 will be repeated for each of the four study periods. These treatments and inspections will be the same across all four study periods with the only difference being the settings on the NMN device used to deliver the fluorescein-dyed saline aerosol. Additionally, for study periods from 2-4, a brief endoscopic inspection will take place between Steps 1 and 2 above to ensure that all fluorescein-dyed saline from the previous assessment has been washed out..
The washout period consists of flushing both nasals with two bottles of saline (50ml each bottle) after each treatment period.
Intervention code [1] 295945 0
Treatment: Devices
Comparator / control treatment
1-2ml of fluorescein-dyed saline without any pulse frequency delivered by the Nasal Mesh Nebulizer (NMN)
Control group
Active

Outcomes
Primary outcome [1] 299685 0
The primary outcome is a composite outcome to evaluate and compare the deposition of fluorescein-dyed saline delivered with the NMN device at different pulse frequencies within the nasal cavities of patients that have undergone FESS.

The quantitative assessment of nasal deposition, clearance and retention will be determined by measurements of the total area of deposition of fluorescein-dyed saline and the intensity of fluorescein at each surgical site (surgically expanded ostia of the paranasal sinuses and oropharynx). Endoscopic videos will be taken at each of the four time points (T0, T5, T10, T15) for each of the sites. Screenshots of these endoscopic videos will be imported into PhotoShop (Adobe Systems, Inc. San Jose, CA) and normalized to a standard images size (605 x 450 pixels). A Lasso tool (tolerance 20) will be used to select portions of the still image containing enough fluorescein to be discerned by the program. The total area of distribution (mm2) will be estimated by comparing the total number of fluorescein-laden pixels captured to the number of pixels subtended by a paper square of known dimensions placed at each surgical site. Additionally, the histogram resulting from the lasso portion of the image will be used to estimate total fluorescein intensity, which is expressed as the mean intensity multiplied by the number of captured pixels (channel, green).
Timepoint [1] 299685 0
The primary endpoint is a composite endpoint which is the total area of deposition of fluorescein-dyed saline at 5 sites within the nasal cavity (surgically expanded ostia of the paranasal sinuses, and oropharynx) immediately after administration between T0 and T15 (at T0, T5, T10 and T15).
Secondary outcome [1] 327846 0
To evaluate and compare the clearance of fluorescein-dyed saline delivered with the NMN device at different pulse frequencies within the nasal cavities of patients that have undergone FESS.
Timepoint [1] 327846 0
Clearance of fluorescein-dyed saline over 15 minutes (at T0, T5, T10, T15) at all 5 sites. The intensity of fluorescein will be evaluated from the screenshots obtained from the endoscopic videos taken immediately following adminstration and at 5, 10 and 15 minutes thereafter. Clearance will be calculated as the linear decrement in fluorescien intensity (mean intensity X number of pixels) between T0 and T25. The 15 minutes duration of assessment is consistent with previous studies and is expected given the known of mucociliary clearance in the paranasal sinuses.

Secondary outcome [2] 327847 0
The other secondary outcome is to evaluate and compare the retention of fluorescein-dyed saline delivered with the NMN device at different pulse frequencies within the nasal cavities of patients that have undergone FESS.
Timepoint [2] 327847 0
The retention will be calculated as:
1. Retention of fluorescein-dyed saline over 15 minutes (at T0, T5, T10, T15) expressed as the Area Under the Curve between T0 and T15 (AUC0-15) of the total area of deposition of fluorescein-dyed saline at all 5 sites
2. Retention of fluorescein-dyed saline over 15 minutes ( at T0, T5, T10, T15) expressed as the AUC0-15 of the intensity of fluorescein-dyed saline at all 5 sites
Secondary outcome [3] 327848 0
The third secondary outcome is to generate a variable that takes into account both the total area of deposition of fluorescein and intensity of fluorescein.
Timepoint [3] 327848 0
1. Intensity-adjusted total area of deposition of fluorescein-dyed saline at 5 sites
2. Retention of fluorescein-dyed saline over 15 minutes expressed as the AUC0-15 of the intensity adjusted total area of fluorescein-dyed saline at all 5 sites

It is expected that the suitable variable will be the Intensity-adjusted Total Area of Deposition: the product of the total area of deposition (primary endpoint) and the mean intensity (expressed as a proportion of maximum intensity [255 on PhotoShop]) of the fluorescein captured in the screenshots at T0. If this is suitable then both the total area of deposition at T0 and the retention of fluorescein-dyed saline between T0 and T15 (i.e. the AUC0-15 of the intensity-adjusted total area of deposition of fluorescein-dyed saline) will be assessed using this variable as exploratory endpoints.
These endpoints will be compared between each pulse frequency and the continuous delivery for each site.
Secondary outcome [4] 328127 0
Clinical safety assessment
Timepoint [4] 328127 0
Safety will be assessed by the incidence of treatment-emergent adverse events over the course of the study. Participant will be specifically asked about the most common side-effects (such as irritation and stinging) as well as other symptoms that may have experienced, at the end of study.

Eligibility
Key inclusion criteria
1. Participants (both males and females) that have undergone Functional Endoscopic Sinus Surgery (FESS) more than 3 months before the study
2. Age >= 18 years
3. No history of smoking
4. No history of chronic lung diseases including asthma, cystic fibrosis, tuberculosis, chronic obstructive lung disease
5. Normal lung function with stable and reproducible baseline FEV1 of >80% of predicted value following adjustment for height, age, and gender (according to the Global Lung Initiative equation)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Significant upper and/or lower respiratory tract infection within the previous 4 weeks
2. History of recurrent lung infections
3. History of chronic lung diseases
4. History of severe or multiple allergies, including hay-fever and perennial rhinitis
5. Participants using nasal decongestant within 14 days of entering the study
6. Participants with documented or suspected, clinically significant alcohol or drug abuse
7. Known history of adverse reaction to fluorescein

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
A randomization list will be generated and each eligible subject will be assigned to a unique randomization number in sequential order.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
The randomization table generated from the computer program includes the treatment sequence that each subject will received during each study period
Phase
Phase 1 / Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Subject Characteristics
Participant demographic and background characteristics will be descriptively summarized using means, standard deviations, ranges, frequencies and percentages as appropriate.

Nasal Deposition Analyses
Between-treatment differences in total area of deposition and clearance at each site will be compared by means of one-way analysis of variance (ANOVA) with pulse frequency as factor.
For measures of retention over 15 minutes, between treatment differences will be compared by means of one-way analysis of covariance (ANCOVA) with pulse frequency as a factor and T0 value as a covariate.

Safety analyses
Data listings will be provided for protocol specified safety data. The Medical Dictionary for Regulatory Activities (MedDRA) (Version 9.1 or higher) will be used to classify all AEs with respect to system organ class and preferred term. Adverse event summaries will include only treatment emergent AEs, which will be summarized for each treatment group. If frequencies permit Fisher’s 2 sided exact test may be used to compare the rates of occurrence between treatment groups

Recruitment
Recruitment status
Stopped early
Data analysis
No data analysis planned
Reason for early stopping/withdrawal
Participant recruitment difficulties
Safety concerns
Other reasons/comments
Other reasons
The technique (taking the images during the endoscopic procedure) used in the current study protocol is not suitable to assess the primary endpoint.
Date of first participant enrolment
Anticipated
31/01/2017
Actual
26/06/2017
Date of last participant enrolment
Anticipated
31/03/2018
Actual
20/07/2017
Date of last data collection
Anticipated
7/04/2018
Actual
13/11/2017
Sample size
Target
20
Accrual to date
Final
2
Recruitment outside Australia
Country [1] 8249 0
New Zealand
State/province [1] 8249 0
Auckland

Funding & Sponsors
Funding source category [1] 294551 0
Commercial sector/Industry
Name [1] 294551 0
AFT Pharmaceuticals Ltd.
Country [1] 294551 0
New Zealand
Primary sponsor type
Commercial sector/Industry
Name
AFT Pharmaceuticals Ltd.
Address
Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622 New Zealand
Country
New Zealand
Secondary sponsor category [1] 293421 0
None
Name [1] 293421 0
Address [1] 293421 0
Country [1] 293421 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295989 0
Northern B Health and Disability Ethics Committee
Ethics committee address [1] 295989 0
Ethics committee country [1] 295989 0
New Zealand
Date submitted for ethics approval [1] 295989 0
29/09/2016
Approval date [1] 295989 0
13/12/2016
Ethics approval number [1] 295989 0
16/NTB/190

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 69162 0
Prof Richard Douglas
Address 69162 0
Mauranui Clinic
86 Great South Rd, Epsom, Auckland 0646, New Zealand
Country 69162 0
New Zealand
Phone 69162 0
+(64) 27 2186083
Fax 69162 0
Email 69162 0
[email protected]
Contact person for public queries
Name 69163 0
Hartley Atkinson
Address 69163 0
AFT Pharmaceuticals Ltd, Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622 New Zealand
Country 69163 0
New Zealand
Phone 69163 0
+ 64 9 488 02 32
Fax 69163 0
Email 69163 0
[email protected]
Contact person for scientific queries
Name 69164 0
Hartley Atkinson
Address 69164 0
AFT Pharmaceuticals Ltd, Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622 New Zealand
Country 69164 0
New Zealand
Phone 69164 0
+ 64 9 488 0232
Fax 69164 0
Email 69164 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.